La Jolla Pharmaceutical Company Revenue and Competitors
Estimated Revenue & Valuation
- La Jolla Pharmaceutical Company's estimated annual revenue is currently $15M per year.
- La Jolla Pharmaceutical Company's estimated revenue per employee is $153,061
- La Jolla Pharmaceutical Company's total funding is $190.9M.
Employee Data
- La Jolla Pharmaceutical Company has 98 Employees.
- La Jolla Pharmaceutical Company grew their employee count by -16% last year.
La Jolla Pharmaceutical Company Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is La Jolla Pharmaceutical Company?
La Jolla Pharmaceutical Company (LJPC) is a biopharmaceutical company that is focused on the research and development of highly specific therapeutics for the treatment of certain life-threatening antibody-mediated diseases. These diseases, including autoimmune conditions such as lupus and antibody-mediated stroke, are caused by abnormal B cell production of antibodies that attack healthy tissues. The Company\'s drug candidates, called Toleragens, are designed to treat the underlying cause of many antibody-mediated diseases without the severe, adverse side effects common to other treatments. The Company is analyzing data from a Phase III clinical trial of its lupus drug candidate, LJP 394, and its clinical drug candidate for the treatment of antibody-mediated thrombosis, known as LJP 1082, is currently being evaluated in toxicology studies that are required prior to the initiation of clinical trials.
keywords:N/A
$190.9M
Total Funding
98
Number of Employees
$15M
Revenue (est)
-16%
Employee Growth %
N/A
Valuation
N/A
Accelerator
La Jolla Pharmaceutical Company News
... GlaxoSmithKline plc, Incyte Corporation, Gamida Cell, Kiadis Pharma, La Jolla Pharmaceutical Company, IONIS Pharmaceuticals.
Daiichi Sankyo Company Ltd; La Jolla Pharmaceutical Company; Oncodesign Sa; Tolero Pharmaceuticals Inc Activin Receptor Type 1 Market Breakdown by Type: Ljpc...
... Genzyme Corporation, La Jolla Pharmaceutical Company, Merck & Co., Inc. ... vendor landscape and important company profiles,medical disposable market...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $27M | 98 | -7% | $19.5M |
#2 | $34.6M | 98 | 2% | N/A |
#3 | $16M | 98 | 5% | N/A |
#4 | $15.2M | 98 | -4% | $156.1M |
#5 | $14.7M | 98 | 8% | N/A |